Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
Immunome, a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, announces the granting of inducement awards to four new employees. On January 2, 2025, the Compensation Committee of Immunome’s Board of Directors announces the approval of non-statutory stock options under the Company’s 2024 Inducement Plan. These inducement awards, totaling 45,000 shares of common stock, are announced as a material inducement for the employees’ employment with the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
Inducement Awards to Support New Talent
Immunome announces that the granting of stock options is a strategic initiative to attract and retain top-tier talent, crucial to advancing the company’s mission of developing cutting-edge cancer therapies. The new stock options granted have an exercise price of $10.53 per share, aligned with the company’s closing sales price on January 2, 2025. These options will vest over a four-year period, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date. The remaining shares will vest monthly over the subsequent 36 months, provided the new employees remain in service with the company through the applicable vesting dates.
This vesting schedule is designed to align the interests of the new employees with the long-term success of Immunome, encouraging continued contributions to the company’s growth and innovation. Immunome announces that the options are granted under the terms and conditions of Immunome’s 2024 Inducement Plan, and each employee is required to sign an applicable stock option agreement that outlines the specific terms of their grant.
A Strong Foundation in Targeted Oncology
Immunome announces its commitment to attracting top professionals who will play a vital role in driving the company’s mission forward. As a clinical-stage company, Immunome is dedicated to advancing targeted oncology therapies that have the potential to significantly improve patient outcomes. The company’s expertise lies in the development of antibody-drug conjugates (ADCs), which are designed to selectively target cancer cells while minimizing damage to surrounding healthy tissue.
The company’s pipeline includes a range of promising therapies, with a particular focus on developing new treatments for cancer patients who have limited options. One of the company’s leading candidates, AL102, a gamma secretase inhibitor, is currently undergoing a Phase 3 clinical trial for the treatment of desmoid tumors. This drug holds great promise for patients suffering from this rare and often difficult-to-treat cancer.
In addition to AL102, Immunome announces that it is advancing several other pipeline candidates, including IM-1021, a ROR1-targeting ADC, and IM-3050, a FAP-targeted radioligand. Both of these therapies are expected to submit Investigational New Drug (IND) applications by the first quarter of 2025, marking important milestones in the company’s quest to bring innovative cancer treatments to market.
A Vision for the Future of Cancer Treatment
Immunome announces that it is led by a team of experts who have played critical roles in the design, development, and commercialization of some of the most advanced cancer therapies available today. With deep expertise in ADCs and other targeted therapies, Immunome is well-positioned to drive significant advancements in the field of oncology.
The company’s vision is to provide patients with new treatment options that offer better efficacy, fewer side effects, and improved quality of life. By leveraging its expertise in targeted therapies and working with some of the brightest minds in biotechnology, Immunome announces its commitment to bringing groundbreaking therapies to the forefront of cancer treatment.
As Immunome continues to expand its pipeline and build a strong team of experts, the company is poised for continued success in the oncology field. The granting of inducement awards to new employees is just one example of how Immunome announces its ongoing investment in its future and ensures that its team has the expertise and motivation to drive its mission forward.
About Immunome
Immunome is a clinical-stage targeted oncology company with a robust portfolio of first-in-class and best-in-class therapies. The company’s innovative pipeline includes a variety of targeted therapies, with a particular focus on antibody-drug conjugates (ADCs) designed to treat cancer. In addition to AL102, which is currently in Phase 3 trials for desmoid tumors, Immunome is advancing other promising candidates, including IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand. Both are set to file INDs by the first quarter of 2025.
Immunome’s leadership team has extensive experience in the development of targeted cancer therapies and is dedicated to improving patient outcomes through groundbreaking treatments. By combining innovative science with a patient-centered approach, Immunome announces its position at the forefront of revolutionizing cancer care.
